Refining Combination Locoregional Therapy for Intermediate-Stage Hepatocellular Carcinoma-Lessons From the TORCH Trial [0.03%]
TORCH研究指导下的中 stage 肝癌综合局部区域治疗的优化
Cynthia Yeung,Howard Lim
Cynthia Yeung
Jiayu Wang,Binghe Xu
Jiayu Wang
Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial [0.03%]
不可切除性肝细胞癌的经动脉化疗栓塞联合消融治疗：TORCH随机临床试验
Ning Lyu,Jun-Zhe Yi,Xin-Tong Wu et al.
Ning Lyu et al.
Importance: Transarterial chemoembolization (TACE) is the standard of care for liver-confined hepatocellular carcinoma (HCC) that is not amenable to curative treatment; however, TACE has demonstrated unsatisfactory surviv...
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial [0.03%]
关于早期高危ERBB2阴性乳腺癌新辅助化疗中使用Cemiplimab和Fianlimab的I-SPY2随机临床试验
Claudine Isaacs,Rita Nanda,Christina Yau et al.
Claudine Isaacs et al.
Importance: Although adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves outcomes in high-risk early-stage breast cancer, opportunities remain to further enhance response. Dual checkpoint blockade off...
Osman Bilge Kaya,Berkan Karabuga,Mustafa Buyukkor
Osman Bilge Kaya
Hongbo Li
Hongbo Li
Survival Language [0.03%]
生存语言
Yosra Raziani
Yosra Raziani
Vivek Subbiah,Chadi Nabhan
Vivek Subbiah
Published Erratum
JAMA oncology. 2026 Jul 23:e262846. DOI:10.1001/jamaoncol.2026.2846 2026
Polina Shilo
Polina Shilo